Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2025-12-25 @ 10:40 PM
Study NCT ID:
NCT01970267
Status:
COMPLETED
Last Update Posted:
2016-04-21
First Post:
2013-10-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Clear Vision Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020255', 'term': 'Vitreous Detachment'}, {'id': 'C000726608', 'term': 'vitreous floaters'}], 'ancestors': [{'id': 'D005128', 'term': 'Eye Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 35}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-04', 'completionDateStruct': {'date': '2016-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-04-20', 'studyFirstSubmitDate': '2013-10-22', 'studyFirstSubmitQcDate': '2013-10-25', 'lastUpdatePostDateStruct': {'date': '2016-04-21', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-10-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Efficacy of the laser treatment measured by the improvement of visual acuity and floater specific Visual Function Questionnaire (VFQ).', 'timeFrame': 'after the last treatment session (approximately 5 days)'}], 'secondaryOutcomes': [{'measure': 'Number of complications in the laser treated eyes compared to the non-treated eyes', 'timeFrame': '6 months'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Posterior Vitreous Detachment', 'Vitreous Floaters']}, 'descriptionModule': {'briefSummary': 'Vitreous floaters are tiny, cloudy, clumps of cells that appear in the otherwise clear fluid (vitreous) that fills the back 3/4 of the eye. Floaters are commonly caused by eye conditions such as posterior vitreous detachment (PVD), vitreous syneresis and asteroid hyalosis. While these symptoms are considered physiological in nature, they can be of considerable inconvenience to many patients which affect essential activities. The investigators wish to assess the safety and efficacy of floater treatment in patients with highly symptomatic floaters using an FDA approved nanosecond infrared yttrium aluminum garnet (YAG) lasers.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '19 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Have been diagnosed with symptomatic floaters lasting more than 2 months\n* Willing to proceed with intervention\n* Be able to provide informed consent\n* Diagnosed with Posterior Vitreous Detachment\n* Accept a 1% risk of complications\n\nExclusion Criteria:\n\n* Less than 19 years of age\n* Is a high myope (greater than -6 diopters)\n* Has monocular vision\n* Diagnosed with asteroid hyalosis\n* Diagnosed with acute on-set of floaters (less than two months and may clear spontaneously)\n* Has corneal or lenticular opacities or any media opacity which may interfere with treatment\n* Has any concomitant ocular disease or pathology\n* Has elevated intraocular pressure (IOP) or on IOP lowering medication\n* Has floaters that are deemed to require more than five treatment sessions, where surgical intervention is the best treatment course\n* Has floaters inaccessible with current lasers and lenses\n* Has floaters located less than 2mm from the crystalline lens or the retina\n* Found to have retinal tears or retinal detachment on initial examination or has had a history of retinal detachment repair within the last two years\n* Has psychiatric problems that may recur or worsen\n* Incapacity to provide informed consent'}, 'identificationModule': {'nctId': 'NCT01970267', 'briefTitle': 'Clear Vision Study', 'organization': {'class': 'OTHER', 'fullName': 'University of British Columbia'}, 'officialTitle': 'Randomized Trial of Laser Ablation for Highly Symptomatic Floaters', 'orgStudyIdInfo': {'id': 'H13-01836'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Laser Treated', 'description': 'Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions', 'interventionNames': ['Procedure: Laser Ablation of Floaters']}, {'type': 'SHAM_COMPARATOR', 'label': 'Not Treated', 'interventionNames': ['Procedure: Sham Laser Treatment']}], 'interventions': [{'name': 'Laser Ablation of Floaters', 'type': 'PROCEDURE', 'armGroupLabels': ['Laser Treated']}, {'name': 'Sham Laser Treatment', 'type': 'PROCEDURE', 'description': 'Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.', 'armGroupLabels': ['Not Treated']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'V5Z 1K1', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'West Coast Retina Consultants Clinic', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'V5Z 3N9', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Eye Care Centre, Vancouver General Hospital', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}], 'overallOfficials': [{'name': 'Andrew B Merkur, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'University of British Columbia'}, {'name': 'Mei Young, MASc', 'role': 'STUDY_DIRECTOR', 'affiliation': 'University of British Columbia'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of British Columbia', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}